LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway

• Published in: Apoptosis (London) Vol. 22; no. 12; pp. 1543 - 1552
• Main Authors: Sun, Kai-Xuan, Wu, Dan-Dan, Chen, Shuo, Zhao, Yang, Zong, Zhi-Hong
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.12.2017; Springer; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; Apoptosis; B cells; Biochemistry; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Carcinoma; Cell Biology; Cell proliferation; Endometrial cancer; Endometrium; Immunoprecipitation; Implantation; Kinases; Metastases; Nucleotides; Oncology; Original Paper; Proteins; Ribonucleic acid; RNA; Signal transduction; Signaling; Tumor suppressor genes; Tumorigenesis; Tumors; Uterine cancer; Virology; Xenografts; MEG3; LncRNA; Endometrial carcinoma; Tumorigenesis and progression
• ISSN: 1360-8185; 1573-675X; 1573-675X
• DOI: 10.1007/s10495-017-1426-7

Long noncoding RNAs (lncRNAs) are RNA molecules more than 200 nucleotides in length that do not encode proteins. Recent studies have reported increasing numbers of functional lncRNAs. Maternally expressed gene 3 (MEG3) is a maternally imprinted gene encoding an lncRNA that plays a tumor suppressor role in various tumors. However, there has been rare report on mechanism of tumorigenesis and progression of endometrial carcinoma. In the present study, we found significantly lower MEG3 expression in endometrial carcinoma tissues than in normal endometrial tissues. MEG3 overexpression inhibited endometrial cancer cell proliferation, invasion, and metastasis; promoted apoptosis; and inhibited the activation of the phosphoinositide 3-kinase (PI3K)/m-TOR signaling pathway. RNA immunoprecipitation assay (RIP) showed that MEG3 can combine directly with PI3K. Tumor xenograft implantation in nude mice showed that MEG3 could significantly suppress tumor growth. These findings provide potential new therapeutic targets for treating endometrial cancer.